Skip to main content

Mefway (18F)









Mefway (18F)


From Wikipedia, the free encyclopedia

Jump to navigation
Jump to search


















































Mefway (18F)
Mefway 18F skeletal.svg
Clinical data
Pregnancy
category

  • N/A
ATC code
  • none
Legal status
Legal status

  • Research compound
Identifiers
CAS Number
  • 943962-60-5

PubChem CID
  • 11963740
ChemSpider
  • 10137857
Chemical and physical data
Formula
C26H35FN4O2
Molar mass 453.583 g/mol
3D model (JSmol)
  • Interactive image

Mefway is a serotonin 5-HT1A receptor antagonist used in medical research, usually in the form of mefway (18F) as a positron emission tomography (PET) radiotracer.[1]




Contents






  • 1 Chemistry


  • 2 Animal PET studies


  • 3 Human PET studies


  • 4 References





Chemistry[edit]


Mefway is closely related to the research compound WAY-100,635. The compound adds a fluoromethyl group to the cyclohexyl ring of WAY-100,635 and it is effectively prepared with automation module.[2]
There are two isomers with regard to the cyclohexane ring, of which the trans conformation has the higher 5-HT1A specificity.[3]


Mefway cis-trans comparison.svg


Animal PET studies[edit]


In one study the uptake and retention of mefway (18F) was found to be similar to that found for 11C-WAY-100,635. Head-to-head comparison of mefway (18F) and 11C-WAY-100,635 have been evaluated. Since 11C-WAY-100,635 is the current ‘gold standard’ and difficult to synthesize, a suitable fluorine-18 replacement as in mefway is highly desired.[4] In addition, mefway (18F) showed comparable brain uptake and the target-to-reference ratios compared to fcway(18F)[5]


The ability to separately measure dissociation constant, KD and receptor density Bmax has been shown to be of potential value rather than simply comparing binding potential, BPND. Multiple injection mefway PET experiments can be used for the in-vivo measurement of 5-HT1A receptor density.[6]


Imaging studies of mefway on in vivo and ex vivo rat brains indicate that the substance binds to the known 5-HT1A receptor regions including the dorsal raphe. These findings support that the dorsal raphe is measurable in rat PET studies.[7] Mefway (18F) undergoes in vivo defluorination in rodent brain and this phenomenon was effectively suppressed by cytochrome P450 inhibitor (i.e. fluconazole).[8] Animal models of Parkinson's disease and the acute physical stress model exhibited significant decrement of binding potential in the hippocampus [9][10]



Human PET studies[edit]


First-in-human studies have shown in vivo stability of mefway (18F) and its localization to 5-HT1A receptor-rich regions in the human brain, including the raphe nucleus.[11] Mefway (18F) is highly selective for the human serotonin 5-HT1A receptor and may therefore may be used to quantify serotonin 5-HT1A receptor distribution in brain regions for the study of various central nervous system disorders.[12]



References[edit]





  1. ^ Saigal, N.; Pichika, R.; Easwaramoorthy, B.; Collins, D.; Christian, B. T.; Shi, B.; Narayanan, T. K.; Potkin, S. G.; Mukherjee, J. (2006). "Synthesis and biologic evaluation of a novel serotonin 5-HT1A receptor radioligand, 18F-labeled mefway, in rodents and imaging by PET in a nonhuman primate". Journal of Nuclear Medicine. 47 (10): 1697–1706. PMID 17015907..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"""""""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  2. ^ Choi, JY; Kim, CH; Ryu, YH; Seo, YB; Truong, P; Kim, EJ; Choi, TH; Kang, J; Lee, M; Kim, DG; Lee, JD; Jeon, TJ (2013). "Optimization of the radiosynthesis of [18F]MEFWAY for imaging brain serotonin 1A receptors by using the GE TracerLab FXFN-Pro module". Journal of labelled compounds & radiopharmaceuticals. 56 (12): 589–94. doi:10.1002/jlcr.3067. PMID 24285234.


  3. ^ Wooten, D.; Hillmer, A.; Murali, D.; Barnhart, T.; Schneider, M. L.; Mukherjee, J.; Christian, B. T. (2011). "An in vivo comparison of cis- and trans-[18F]mefway in the nonhuman primate". Nuclear Medicine and Biology. 38 (7): 925–32. doi:10.1016/j.nucmedbio.2011.04.001. PMC 3190069. PMID 21741252.


  4. ^ Wooten, D. W.; Moraino, J. D.; Hillmer, A. T.; Engle, J. W.; Dejesus, O. J.; Murali, D.; Barnhart, T. E.; Nickles, R. J.; Davidson, R. J.; Schneider, M. L.; Mukherjee, J.; Christian, B. T. (2011). "In vivo kinetics of F-18]MEFWAY: A comparison with C-11]WAY100635 and F-18]MPPF in the nonhuman primate". Synapse. 65 (7): 592–600. doi:10.1002/syn.20878. PMC 3080024. PMID 21484878.


  5. ^ Choi, JY; Kim, BS; Kim, CH; Kim, DG; Han, SJ; Lee, K; Kim, KM; An, G; Choi, TH; Yoo, SD; Ryu, YH (2014). "Translational possibility of [18 F]Mefway to image serotonin 1A receptors in humans: Comparison with [18 F]FCWAY in rodents". Synapse. 68 (12): 595–603. doi:10.1002/syn.21771. PMID 25056144.


  6. ^ Wooten, D. W.; Hillmer, A. T.; Moirano, J. M.; Ahlers, E. O.; Slesarev, M.; Barnhart, T. E.; Mukherjee, J.; Schneider, M. L.; Christian, B. T. (2012). "Measurement of 5-HT1A receptor density and in-vivo binding parameters of 18F]mefway in the nonhuman primate". Journal of Cerebral Blood Flow & Metabolism. 32 (8): 1546–1558. doi:10.1038/jcbfm.2012.43. PMC 3421091. PMID 22472611.


  7. ^ Saigal, N.; Bajwa, A. K.; Faheem, S. S.; Coleman, R. A.; Pandey, S. K.; Constantinescu, C. C.; Fong, V.; Mukherjee, J. (2013). "Evaluation of serotonin 5-HT1Areceptors in rodent models using 18F]mefway PET". Synapse. 67 (9): 596–608. doi:10.1002/syn.21665. PMC 3744326. PMID 23504990.


  8. ^ Choi, JY; Kim, CH; Jeon, TJ; Kim, BS; Yi, CH; Woo, KS; Seo, YB; Han, SJ; Kim, KM; Yi, DI; Lee, M; Kim, DG; Kim, JY; Lee, KC; Choi, TH; An, G; Ryu, YH (December 2012). "Effective microPET imaging of brain 5-HT(1A) receptors in rats with [(18) F]MeFWAY by suppression of radioligand defluorination". Synapse. 66 (12): 1015–23. doi:10.1002/syn.21607. PMID 22927318.


  9. ^ Lee, M; Ryu, Y. H.; Cho, W. G.; Jeon, T. J.; Lyoo, C. H.; Kang, Y. W.; Lee, S. J.; Kim, C. H.; Kim, D. G.; Kang, J. H.; Seo, Y. B.; Yi, C. H.; Lee, K; Choi, T. H.; Choi, J. Y. (2014). "Dopaminergic neuron destruction reduces hippocampal serotonin 1A receptor uptake of trans-(18)FMefway". Applied Radiation and Isotopes. 94: 30–4. doi:10.1016/j.apradiso.2014.06.016. PMID 25064461.


  10. ^ Choi, J. Y.; Shin, S; Lee, M; Jeon, T. J.; Seo, Y; Kim, C. H.; Kim, D. G.; Yi, C. H.; Lee, K; Choi, T. H.; Kang, J. H.; Ryu, Y. H. (2014). "Acute physical stress induces the alteration of the serotonin 1A receptor density in the hippocampus". Synapse. 68 (8): 363–8. doi:10.1002/syn.21748. PMID 24771590.


  11. ^ Hillmer, A. T.; Wooten, D. W.; Bajwa, A. K.; Higgins, A. T.; Lao, P. J.; Betthauser, T. J.; Barnhart, T. E.; Rowley, H. A.; Stone, C. K.; Johnson, S. C.; Mukherjee, J; Christian, B. T. (2014). "First-in-Human Evaluation of 18F-Mefway, a PET Radioligand Specific to Serotonin-1A Receptors". Journal of Nuclear Medicine. 55 (12): 1973–9. doi:10.2967/jnumed.114.145151. PMC 4316674. PMID 25453045.


  12. ^ Mukherjee, J; Bajwa, A. K.; Wooten, D. W.; Hillmer, A. T.; Pan, M. L.; Pandey, S. K.; Saigal, N; Christian, B. T. (2015). "Comparative assessment of 18 F-Mefway as a serotonin 5-HT1A receptor PET imaging agent across species- rodents, nonhuman primates, and humans". Journal of Comparative Neurology. 524 (7): 1457–71. doi:10.1002/cne.23919. PMC 4783179. PMID 26509362.













Retrieved from "https://en.wikipedia.org/w/index.php?title=Mefway_(18F)&oldid=845116069"





Navigation menu

























(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"0.812","walltime":"0.963","ppvisitednodes":{"value":4924,"limit":1000000},"ppgeneratednodes":{"value":0,"limit":1500000},"postexpandincludesize":{"value":322941,"limit":2097152},"templateargumentsize":{"value":3294,"limit":2097152},"expansiondepth":{"value":14,"limit":40},"expensivefunctioncount":{"value":3,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":41335,"limit":5000000},"entityaccesscount":{"value":3,"limit":400},"timingprofile":["100.00% 665.717 1 -total"," 55.97% 372.571 1 Template:Drugbox"," 38.53% 256.506 1 Template:Infobox"," 33.04% 219.922 1 Template:Reflist"," 28.51% 189.790 12 Template:Cite_journal"," 16.85% 112.144 18 Template:Navbox"," 11.78% 78.403 16 Template:Unbulleted_list"," 8.72% 58.049 1 Template:Serotonergics"," 7.79% 51.851 1 Template:Infobox_drug/chemical_formula"," 2.39% 15.884 1 Template:Infobox_drug/maintenance_categories"]},"scribunto":{"limitreport-timeusage":{"value":"0.294","limit":"10.000"},"limitreport-memusage":{"value":4900297,"limit":52428800}},"cachereport":{"origin":"mw1321","timestamp":"20181216025817","ttl":1900800,"transientcontent":false}}});});{"@context":"https://schema.org","@type":"Article","name":"Mefway (18F)","url":"https://en.wikipedia.org/wiki/Mefway_(18F)","sameAs":"http://www.wikidata.org/entity/Q6807950","mainEntity":"http://www.wikidata.org/entity/Q6807950","author":{"@type":"Organization","name":"Contributors to Wikimedia projects"},"publisher":{"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":{"@type":"ImageObject","url":"https://www.wikimedia.org/static/images/wmf-hor-googpub.png"}},"datePublished":"2011-08-05T18:42:08Z","dateModified":"2018-06-09T14:01:13Z","image":"https://upload.wikimedia.org/wikipedia/commons/2/2a/Mefway_18F_skeletal.svg","headline":"chemical compound"}(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgBackendResponseTime":122,"wgHostname":"mw1268"});});
-

Popular posts from this blog

Full-time equivalent

Image
Full-time equivalent From Wikipedia, the free encyclopedia Jump to navigation Jump to search Full-time equivalent ( FTE ) or whole time equivalent ( WTE ) is a unit that indicates the workload of an employed person (or student) in a way that makes workloads or class loads comparable [1] across various contexts. FTE is often used to measure a worker's or student's involvement in a project, or to track cost reductions in an organization. An FTE of 1.0 is equivalent to a full-time worker or student, while an FTE of 0.5 signals half of a full work or school load. [2] Contents 1 U.S. Federal Government 2 In education 2.1 Example 3 Notes 4 References U.S. Federal Government [ edit ] In the U.S. Federal Government, FTE is defined by the Government Accountability Office (GAO) as the number of total hours worked divided by the maximum number of compensable hours in a full-time schedule as...
Read more

さくらももこ

Image
さくら ももこ 本名 非公開 [1] 生誕 ( 1965-05-08 ) 1965年5月8日 日本・静岡県清水市 （現・静岡市清水区） 死没 ( 2018-08-15 ) 2018年8月15日（53歳没） 日本・東京都目黒区 国籍 日本 職業 漫画家 エッセイスト 作詞家 活動期間 1984年 - 2018年 ジャンル 少女漫画 青年漫画 児童漫画 代表作 『ちびまる子ちゃん』 『コジコジ』 受賞 1989年：第13回講談社漫画賞少女部門 （『ちびまる子ちゃん』） 1990年：第32回日本レコード大賞 （『おどるポンポコリン』作詞） 公式サイト さくらプロダクション テンプレートを表示 さくら ももこ （1965年5月8日 - 2018年8月15日 [2] ）は、日本の漫画家、エッセイスト、作詞家、脚本家。また、自身の少女時代をモデルとした代表作のコミック『ちびまる子ちゃん』の主人公の名前でもある。静岡県清水市（現・静岡市清水区）出身。血液型はA型。身長159cm。一男の母親。 代表作のコミック『ちびまる子ちゃん』の単行本の売上は累計3000万部を超える。また、エッセイストとしても独特の視点と語り口で人気が高く、初期エッセイ集三部作『もものかんづめ』『さるのこしかけ』『たいのおかしら』はいずれもミリオンセラーを記録。 目次 1 経歴 2 人物・交遊関係 3 主な作品 3.1 漫画 3.2 エッセイ 3.3 作詞 3.4 詩集 3.5 雑誌・ムック本 3.6 翻訳 3.7 絵本、ドラマ脚本他 3.8 ラジオ出演 3.9 その他 4 関係人物 4.1 アシスタント 4.2 さくらももこを演じた人物 5 脚注 5.1 注釈 5.2 出典 6 外部リンク 経歴 年譜形式の経歴は推奨されていません 。人物の伝記は流れのあるまとまった文章で記述し、年譜は補助的な使用にとどめてください。 （ 2018年8月 ） 清水市立（当時）入江小学校...
Read more

13 indicted, 8 arrested in Calif. drug cartel investigation

Image
Fox News U.S. World Opinion Politics Entertainment Business Lifestyle TV Radio More Expand / Collapse search Login Watch TV ☰ Hot Topics U.S. Crime Military Education Terror Immigration Economy Personal Freedoms World U.N. Conflicts Terrorism Disasters Global Economy Environment Religion Scandals Opinion Politics Executive Senate House Judiciary Foreign policy Polls Elections Entertainment Celebrity News Movies TV News Music News Style News Entertainment Video Business Markets Politics Technology Features Business Leaders Lifestyle Food + Drink Cars + Trucks Travel + Outdoors House + Home Fitness + Well-being Style + Beauty Family Science Archaeology Air & Space Planet Earth Wild Nature Natural Science Dinosaurs Tech Security Innovation Drones Computers Video Games Military Tech Health Healthy Living Medical Research Mental Health Cancer Heart Health Children'...
Read more